Journal article
Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk.
Authors
Eaton MD CB
Journal
Annals of Internal Medicine, Vol. 165, No. 2,
Publisher
American College of Physicians
Publication Date
July 19, 2016
DOI
10.7326/acpjc-2016-165-2-008
ISSN
1056-8751